China is the fourth major market in which the treatment, sold under the brand name Kisunla, has received approval after the United States, Japan and the UK, Lilly said in a statement. It also caused brain swelling in nearly a quarter of patients and brain bleeding in nearly a third,

China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The treatment, designed to slow memory decline and clear brain plaques, offers early-stage patients a